Almac Group’s long-term client partner, Wellstat Therapeutics, received commercial approval of its first orphan drug product XURIDEN (uridine triacetate) for the treatment of rare disease Hereditary Orotic Aciduria (HOA). The partnership began five years ago with Almac providing support for the development of both the API and formulation of the drug product. Having manufactured clinical, registration and PV batches, Almac will now produce the commercial product from its UK headquarter facilit...